Speedus Corp. (SPDE) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 13, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSpeedus Corp. (SPDE) trades at $0.0001. Speedus Corp. operates across diverse sectors, developing diagnostic decision support products and telemedicine systems for healthcare professionals, alongside ultra-high speed storage solutions for server networks. Sector: Healthcare.
Price as of · Last analyzed: Jun 13, 2026Analyst Coverage for SPDE: SPDE does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Speedus Corp. (SPDE) Healthcare & Pipeline Overview
Speedus Corp. is a diversified entity engaged in developing computer-aided medical devices and telemedicine platforms for healthcare, alongside ultra-high speed storage systems for networks. The company also holds a significant FCC spectrum license in New York City and manages a portfolio of marketable securities, positioning it uniquely across technology, healthcare, and telecommunications sectors.
What Is the Investment Thesis for SPDE?
Speedus Corp. presents a unique investment profile due to its highly diversified asset base spanning healthcare technology, high-speed data storage, telecommunications spectrum, and a financial investment portfolio. The company's proprietary medical devices, such as the Zargis Cardioscan and Signal X6, address a critical need for enhanced diagnostic support in primary care and cardiology, potentially offering a pathway to revenue growth through broader adoption in the U.S. healthcare system. Concurrently, its ultra-high speed storage solutions, including JetX10 and JetPod, cater to the increasing demand for data efficiency in server networks, a market driven by continuous digital transformation. A significant, yet currently unmonetized, asset is the FCC commercial operating license for 150–300 MHz of spectrum in the New York City area, which holds substantial strategic value for future telecommunications applications. While the company currently reports a negative profit margin of -616.6% and a high beta of 35.48, indicating significant volatility and unprofitability, its gross margin of 63.9% suggests potential for profitability if sales volumes increase and operational efficiencies are achieved. The strategic management of its investment portfolio also provides an additional, albeit variable, source of potential returns. Investors may consider the long-term potential of these distinct assets, particularly the healthcare technology and the FCC license, as key value drivers for future growth, despite the current financial performance and market capitalization of $0.00B.
Based on FMP financials and quantitative analysis
SPDE Key Highlights
Gross Margin of 63.9% indicates strong profitability on products sold, despite overall negative profit.
- Profit Margin of -616.6% reflects significant operational losses relative to revenue.
- Market Capitalization is $0.00B, indicating a very small market valuation.
- Beta of 35.48 suggests extreme volatility relative to the broader market, making it a high-risk asset.
- The company operates with a lean team of 20 employees, indicating a highly focused or early-stage operational structure.
Who Are SPDE's Competitors?
SPDE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| INBS Intelligent Bio Solutions Inc. | $1.66 | 0.00% | $5.51M | — |
| NDRA ENDRA Life Sciences Inc. | $6.06 | +3.06% | $7.70M | 32 5-pillar |
| ADVB Advanced Biomed Inc. Common Stock | $6.73 | -2.60% | $9.30M | 62 5-pillar |
| BNGO Bionano Genomics, Inc. | $1.48 | -5.73% | $17.0M | — |
| BNR Burning Rock Biotech Limited | $16.25 | +1.63% | $17.2M | — |
| MDXH MDxHealth SA | $0.57 | -0.90% | $29.3M | — |
| QUCY QUCY | $1.34 | -0.74% | $30.5M | — |
| STRR Star Equity Holdings, Inc. | $9.76 | -1.11% | $36.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SPDE's Key Strengths?
Diversified business model across healthcare tech, high-speed storage, and telecommunications spectrum.
- Proprietary medical devices like Zargis Cardioscan offer non-invasive diagnostic capabilities.
- Ownership of a valuable FCC spectrum license in the New York City area.
- Strong gross margin of 63.9% on products sold.
What Are SPDE's Weaknesses?
Significant negative profit margin of -616.6%, indicating substantial unprofitability.
- Very small market capitalization of $0.00B, suggesting limited market presence and liquidity.
- Extremely high Beta of 35.48, indicating high stock price volatility and risk.
- Small operational team of 20 employees may limit scalability and extensive market penetration.
What Are the Key Risks for SPDE?
Continued negative profit margins could deplete capital and hinder future operational expansion and product development.
- High stock volatility (Beta of 35.48) and low market capitalization ($0.00B) present significant investment risk and potential for illiquidity.
- Intense competition in the medical device, high-speed storage, and telecommunications sectors could limit market penetration and profitability.
- The 'Unknown' disclosure status and 'OTC Other' tier classification create transparency issues, making it difficult for investors to assess financial health and operational progress.
- Regulatory hurdles or changes in the healthcare and telecommunications industries could impact the viability or profitability of its core assets and services.
What Are SPDE's Competitive Advantages?
- Proprietary technology in non-invasive diagnostic medical devices (Zargis Cardioscan, Signal X6).
- Specialized ultra-high speed storage system architecture (JetX10, JetPod, JetNode) for niche applications.
- Exclusive FCC commercial operating license for a significant block of spectrum in the New York City area.
- Diversified business model across healthcare tech, storage, telecom, and investments, reducing reliance on a single market.
What Does SPDE Do?
Founded in 1995 and headquartered in Freehold, New Jersey, Speedus Corp., initially known as SPEEDUS.COM, Inc. before its name change in May 2002, has evolved into a multifaceted enterprise operating through its subsidiaries. The company primarily focuses on two distinct technological domains: healthcare diagnostic support and high-speed data storage, while also maintaining a presence in telecommunications and financial investments. In the healthcare sector, Speedus Corp. develops diagnostic decision support products and services tailored for primary care physicians, pediatricians, cardiologists, and other healthcare professionals across the United States. Its offerings include computer-aided medical devices and telemedicine-based delivery systems designed to enhance diagnostic accuracy and efficiency. Key products in this segment are the Zargis Cardioscan device, a non-invasive solution that automatically analyzes acoustical data to detect suspected diastolic or systolic murmurs, and the Signal X6 device, which records heart and lung sounds using six adhesive acoustic sensors. Complementing these devices is the ZargisTelemed portal, facilitating telemedicine services. Beyond healthcare, Speedus Corp. is also involved in the development and marketing of ultra-high speed storage systems. This portfolio includes the JetX10 acceleration appliance, JetPod, and JetNode expansion chassis, which are designed to enhance performance for server networks and various other demanding applications. Furthermore, the company possesses a local multipoint distribution service license, an FCC commercial operating license, which grants it rights to between 150–300 MHz of spectrum within the strategically important New York City area. This license represents a significant asset within the telecommunications landscape. Adding another layer to its diversified business model, Speedus Corp. holds investments in a portfolio of marketable securities, as well as equity and debt instruments of non-publicly held companies, reflecting a strategy that extends beyond its core technological developments.
What Products and Services Does SPDE Offer?
- Develops diagnostic decision support products for primary care physicians, pediatricians, and cardiologists.
- Offers computer-aided medical devices like Zargis Cardioscan for detecting heart murmurs.
- Provides the Signal X6 device for recording heart and lung sounds.
- Operates the ZargisTelemed portal for telemedicine-based delivery systems.
- Develops and markets ultra-high speed storage systems, including JetX10, JetPod, and JetNode.
- Holds an FCC commercial operating license for 150–300 MHz of spectrum in the New York City area.
- Manages a portfolio of marketable securities and investments in non-publicly held companies.
How Does SPDE Make Money?
- Generates revenue from the sale of computer-aided medical devices and associated services.
- Earns income from the development and sales of ultra-high speed storage systems for server networks.
- Holds a valuable FCC spectrum license in the New York City area, which could be monetized through leasing or direct use.
- Derives potential returns from its investment portfolio, including marketable securities and private equity/debt instruments.
What Industry Does SPDE Operate In?
Speedus Corp. operates within a highly diversified industry landscape, making its positioning unique. In the telecommunications services sector, its FCC local multipoint distribution service license for the New York City area places it within the competitive and capital-intensive market for spectrum, a critical asset for wireless communication and data transmission. This segment is characterized by ongoing technological advancements and significant demand for bandwidth. Simultaneously, the company's healthcare technology offerings, including diagnostic decision support products and telemedicine systems, position it within the medical device and digital health industries. These markets are experiencing robust growth driven by an aging population, increasing prevalence of chronic diseases, and the accelerating adoption of telemedicine. The global telemedicine market, for instance, is projected to continue its rapid expansion. Lastly, its ultra-high speed storage systems place it in the enterprise data storage market, which is driven by the exponential growth of data and the need for faster, more efficient data processing solutions. Speedus's strategy appears to be to leverage proprietary technology across these distinct, yet high-growth, segments, rather than focusing on a single, traditional industry niche.
Who Are SPDE's Key Customers?
- Primary care physicians and pediatricians utilizing diagnostic support products.
- Cardiologists and other healthcare professionals employing specialized medical devices.
- Server networks and other applications requiring ultra-high speed storage systems.
- Potential telecommunications service providers or entities interested in spectrum utilization in NYC.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
Speedus Corp. operates in the Healthcare sector. It is headquartered in Freehold, US. The company is led by CEO Shant S. Hovnanian. SPDE has traded publicly since 1996.
Insider Activity
11 transactions · 0 purchases, 2 sales, 9 other transactions · 2 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
SPDE Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
SPDE Latest News
No recent news available for SPDE.
SPDE Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SPDE.
Price Targets
Wall Street price target analysis for SPDE.
SPDE MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for SPDE; grades run from A+ (80-100) to F (below 30).
Leadership: Shant S. Hovnanian
CEO
Specific details regarding Shant S. However, as the head of a company managing operations across diverse technological sectors and an investment portfolio, his role likely involves strategic oversight of product development, market positioning, and financial management for the company's 20 employees.
Track Record: Specific achievements, strategic decisions, or company milestones directly attributable to Shant S. Hovnanian's leadership are not detailed in the provided information. His tenure has overseen the company's continued engagement in healthcare diagnostic products, high-speed storage systems, the maintenance of its FCC spectrum license, and the management of its investment portfolio.
SPDE OTC Market Information
Speedus Corp. trades on the OTC market under the 'OTC Other' tier. This tier represents companies that do not meet the disclosure requirements for OTCQX or OTCQB, or choose not to provide financial information to OTC Markets Group. Companies in this tier often have limited public information available, which can make comprehensive due diligence challenging. Unlike companies listed on major exchanges like NYSE or NASDAQ, which adhere to stringent listing standards including minimum share prices, market capitalization, and regular financial reporting, 'OTC Other' companies have significantly fewer regulatory obligations regarding public disclosure.
- OTC Tier: OTC Other
- Limited Public Information: The 'Unknown' disclosure status means investors have restricted access to financial statements and operational updates, hindering informed decision-making.
- Low Liquidity: Trading on the 'OTC Other' tier often results in minimal trading volume and wide bid-ask spreads, making it difficult to buy or sell shares efficiently.
- Price Volatility: Due to low liquidity and limited information, OTC stocks, especially in the 'OTC Other' tier, can be subject to extreme price fluctuations.
- Lack of Analyst Coverage: Companies in this tier typically receive no coverage from institutional analysts, leaving investors without independent research and valuation insights.
- Potential for Manipulation: The less regulated environment and lower transparency of OTC markets can increase the risk of market manipulation.
- Verify the company's current business operations and revenue streams, if any, beyond the provided description.
- Attempt to locate any available financial statements or disclosures, even if not through official OTC Markets channels.
- Research any news or press releases from the company directly, if available, to understand recent developments.
- Assess the management team's background and track record beyond what is publicly stated, if possible.
- Understand the market for its specific products (healthcare devices, storage systems) and the competitive landscape.
- Evaluate the long-term viability and potential monetization strategies for its FCC spectrum license.
- Consider the inherent risks of investing in illiquid, thinly traded securities with limited public disclosure.
- The company was founded in 1995 and has a history of operations, indicating longevity.
- It possesses tangible assets, including proprietary medical devices, high-speed storage technology, and an FCC spectrum license.
- The company has a stated headquarters in Freehold, New Jersey, and a known CEO.
- Its business description outlines specific products and services, suggesting active engagement in its stated sectors.
Common Questions About SPDE (Healthcare)
What are the main risks for SPDE?
Speedus Corp. faces several significant risks that investors may want to evaluate. Financially, the company's substantial negative profit margin of -616.6% indicates ongoing unprofitability, which can strain its capital resources.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- CEO background and track record details are limited in the provided source data, requiring some inference for the 'title' field and explicit 'Unknown' statements for specific details.
- Word count for each section was meticulously adhered to, sometimes requiring careful phrasing to meet minimums without speculation.
- The 'Unknown' disclosure status for OTC analysis means certain details about financial reporting are inferred based on the 'OTC Other' tier.